Steminent Biotherapeutics (ROCO:7729) Marketable Securities: NT$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7729 Steminent Biotherapeutics Inc ROCO:7729
9 GF Score
Price NT$79.10
! 4 Warning Signs
View Full Analysis

What is Steminent Biotherapeutics Marketable Securities?

Steminent Biotherapeutics ROCO:7729 +1.02% 9 Marketable Securities is NT$0.00 Mil as of Dec. 2025. GuruFocus rates ROCO:7729 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Steminent Biotherapeutics's Marketable Securities for the quarter that ended in Dec. 2025 was NT$0.00 Mil.

Steminent Biotherapeutics's annual Marketable Securities increased from Dec. 2023 (NT$0.00 Mil) to Dec. 2024 (NT$11.60 Mil) but then declined from Dec. 2024 (NT$11.60 Mil) to Dec. 2025 (NT$0.00 Mil).

Steminent Biotherapeutics  (ROCO:7729) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Steminent Biotherapeutics Marketable Securities Related Terms

Steminent Biotherapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Steminent Biotherapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics Marketable Securities Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 11.60 0.00

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 11.60 32.02 0.00
ROCO:7729
9GF Score
Steminent Biotherapeutics Inc ROCO:7729
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steminent Biotherapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$0.00 Mil mean?
Steminent Biotherapeutics (ROCO:7729) has a Marketable Securities of NT$0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Steminent Biotherapeutics and its competitors.
Is Steminent Biotherapeutics' Marketable Securities too high?
Steminent Biotherapeutics' current Marketable Securities is NT$0.00 Mil. Overall, Steminent Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' Marketable Securities compare to VRTX and REGN?
Steminent Biotherapeutics' Marketable Securities of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Steminent Biotherapeutics and its competitors. Steminent Biotherapeutics's current Marketable Securities is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current Marketable Securities of NT$0.00 Mil. The current Marketable Securities is NT$0.00 Mil. Steminent Biotherapeutics' overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current Marketable Securities is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Steminent Biotherapeutics Business Description

Address No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
9GF Score

Get the complete analysis for ROCO:7729

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$79.10
Price